SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
JERUSALEM, Israel, March 12, 2013 /PRNewswire/ –
SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of patent-pending voice
recognition technology that reduces the risks of errors during the administration of
prescription medications, announced today that the company has acquired breakthrough
Quickool technology enabling individuals to self-administer pain free injections.
SafeCode Drug Technologies acquired Quickool and EasyJet technology from Sindolor
Medical Ltd., an Israel-based medical technologies development company.
The technologies enable individuals to safely and painlessly administer injections or
blood lancing, by quickly cooling the site of the injection immediately prior to the
piercing of the skin. The technology is particularly useful for patients with diabetes who
need to test blood-sugar levels or inject themselves regularly with insulin.
In addition, the technology has several other useful applications. SafeCode intends to
publish additional announcements regarding Quickool and EasyJet technologies in the coming
“The acquisition of additional marketable technologies adds significant value to
SafeCode’s existing product line,” said Joel Klopfer, Chief Executive Officer of SafeCode
Drug Technologies. “SafeCode’s voice activated technology simplifies the administration of
prescription medication, and the technology acquired from Sindolor Medical provides
“Making the administration of medicines and blood tests easier and painless has the
potential to save lives, by reducing the chances of potentially life-threatening errors,”
About SafeCode Drug Technologies
SafeCode Drug Technologies is the developer of a patent-pending voice recognition
technology that provides an essential degree of security that can effectively prevent
unauthorized administration of a prescription medication.
This letter contains forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of
1934 as amended. All forward-looking statements are inherently uncertain, based on current
expectations and assumptions concerning future events or future performance of SafeCode
Drug Technologies Corp., and its technologies. In evaluating such statements, prospective
investors should review carefully various risks and uncertainties identified in this
release, as actual results may differ materially from those indicated. SafeCode Drug
Technologies Corp. public filings may be viewed at http://www.sec.gov.
Contact: Joel Klopfer Joel.Klofer1@gmail.com +9722-5021322
SOURCE Safecode Drug Technologies Corp.